Pneumonia in the neutropenic cancer patient
- PMID: 25784246
- PMCID: PMC4429304
- DOI: 10.1097/MCP.0000000000000156
Pneumonia in the neutropenic cancer patient
Abstract
Purpose of review: Pneumonia is the leading cause of death among neutropenic cancer patients, particularly those with acute leukaemia. Even with empiric therapy, case fatality rates of neutropenic pneumonias remain unacceptably high. However, recent advances in the management of neutropenic pneumonia offer hope for improved outcomes in the cancer setting. This review summarizes recent literature regarding the clinical presentation, microbiologic trends, diagnostic advances and therapeutic recommendations for cancer-related neutropenic pneumonia.
Recent findings: Although neutropenic patients acquire pathogens both in community and nosocomial settings, patients' obligate healthcare exposures result in the frequent identification of multidrug-resistant bacterial organisms on conventional culture-based assessment of respiratory secretions. Modern molecular techniques, including expanded use of galactomannan testing, have further facilitated identification of fungal pathogens, allowing for aggressive interventions that appear to improve patient outcomes. Multiple interested societies have issued updated guidelines for antibiotic therapy of suspected neutropenic pneumonia. The benefit of antibiotic medications may be further enhanced by agents that promote host responses to infection.
Summary: Neutropenic cancer patients have numerous potential causes for pulmonary infiltrates and clinical deterioration, with lower respiratory tract infections among the most deadly. Early clinical suspicion, diagnosis and intervention for neutropenic pneumonia provide cancer patients' best hope for survival.
Conflict of interest statement
DEO has no financial conflicts of interest to disclose.
SEE is an author on US Patent 8,883,174 entitled “Compositions for stimulation of mammalian innate immune responses to pathogens,” and owns stock in Pulmotect, Inc., a company that has licensed technology referenced in this manuscript for clinical development.
Figures






Similar articles
-
Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients.Respirology. 2016 Nov;21(8):1411-1418. doi: 10.1111/resp.12848. Epub 2016 Jul 14. Respirology. 2016. PMID: 27417156
-
Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours.J Infect. 2014 Nov;69(5):417-23. doi: 10.1016/j.jinf.2014.05.018. Epub 2014 Jun 21. J Infect. 2014. PMID: 24960295
-
Therapeutic implication of BAL in patients with neutropenia.Ann Hematol. 2009 Dec;88(12):1249-56. doi: 10.1007/s00277-009-0747-1. Epub 2009 May 5. Ann Hematol. 2009. PMID: 19415277
-
Nosocomial pneumonia: aetiology, diagnosis and treatment.Curr Opin Pulm Med. 2006 May;12(3):192-7. doi: 10.1097/01.mcp.0000219268.35063.b0. Curr Opin Pulm Med. 2006. PMID: 16582674 Review.
-
New molecular and surrogate biomarker-based tests in the diagnosis of bacterial and fungal infection in febrile neutropenic patients.Curr Opin Infect Dis. 2010 Dec;23(6):567-77. doi: 10.1097/QCO.0b013e32833ef7d1. Curr Opin Infect Dis. 2010. PMID: 20827189 Review.
Cited by
-
Cancer patients with neutropenic septic shock: etiology and antimicrobial resistance.Korean J Intern Med. 2020 Jul;35(4):979-987. doi: 10.3904/kjim.2018.306. Epub 2019 Oct 28. Korean J Intern Med. 2020. PMID: 31648434 Free PMC article.
-
Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.Clin Chest Med. 2017 Jun;38(2):263-277. doi: 10.1016/j.ccm.2016.12.005. Epub 2017 Mar 1. Clin Chest Med. 2017. PMID: 28477638 Free PMC article. Review.
-
The Diagnostic Utility and Clinical Implications of Bronchoalveolar Lavage in Cancer Patients With Febrile Neutropenia and Lung Infiltrates.Cureus. 2020 Sep 6;12(9):e10268. doi: 10.7759/cureus.10268. Cureus. 2020. PMID: 33042706 Free PMC article.
-
Blocking HXA3-mediated neutrophil elastase release during S. pneumoniae lung infection limits pulmonary epithelial barrier disruption and bacteremia.bioRxiv [Preprint]. 2024 Jun 25:2024.06.25.600637. doi: 10.1101/2024.06.25.600637. bioRxiv. 2024. Update in: mBio. 2024 Sep 11;15(9):e0185624. doi: 10.1128/mbio.01856-24. PMID: 38979170 Free PMC article. Updated. Preprint.
-
What Is Different in Acute Hematologic Malignancy-Associated ARDS? An Overview of the Literature.Medicina (Kaunas). 2022 Sep 3;58(9):1215. doi: 10.3390/medicina58091215. Medicina (Kaunas). 2022. PMID: 36143892 Free PMC article. Review.
References
-
- Joos L, Tamm M. Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy. Proc Am Thorac Soc. 2005;2(5):445–8. - PubMed
-
- WHO. The World Health Report 2004 -- Changing History. Geneva: World Health Organization; 2004.
-
- Ahmed S, Siddiqui AK, Rossoff L, Sison CP, Rai KR. Pulmonary complications in chronic lymphocytic leukemia. Cancer. 2003;98(9):1912–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials